- Molecular NameLoratadine
- SynonymLoratadina [Spanish]; Loratadinum [Latin]
- Weight382.891
- Drugbank_IDDB00455
- ACS_NO79794-75-5
- Show 2D model
- LogP (experiment)5.2
- LogP (predicted, AB/LogP v2.0)5.06
- pka5.0
- LogD (pH=7, predicted)5.05
- Solubility (experiment)0.000011 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-5.47
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors0
- No.of HBond Acceptors4
- No.of Rotatable Bonds2
- TPSA42.43
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antihistamine drug used to treat allergies, and marketed for its non-sedating properties.
- Absorption_value90.0
- Absorption (description)Loratadine is rapidly absorbed after oral administration
- Caco_2N/A
- Bioavailability40.0
- Protein binding97.0
- Volume of distribution (VD)119 L/kg (range 32 to 261)
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic (CYP2D6- and 3A4-mediated). Extensive metabolism. Peak plasma concentrations are observed 1 to 1.5 h after administration. Steady state concentrations are achieved after 5 days. The major metabolite desloratadine (descarboethoxyloratadine) is rapidly formed and has antihistamine activity. It undergoes further oxidation and hydroxylation to several products.
- Half life8 h
- ExcretionExcretion, in the form of metabolites, is via urine and faeces. 27% of a dose is excreted in urine within 24 h and 40% is excreted in urine and 42% in faeces over 10 days. Loratadine and its metabolites are also distributed in breast milk but do not appear to cross the blood–brain barrier to a significant extent.
- Urinary ExcretionNegligible
- Clerance142 ml/kg/min
- ToxicitySomnolence, tachycardia, and headache
- LD50 (rat)LD50=mg/kg
- LD50 (mouse)N/A